1. Home
  2. CSTL vs AHH Comparison

CSTL vs AHH Comparison

Compare CSTL & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • AHH
  • Stock Information
  • Founded
  • CSTL 2007
  • AHH 1979
  • Country
  • CSTL United States
  • AHH United States
  • Employees
  • CSTL N/A
  • AHH N/A
  • Industry
  • CSTL Medical Specialities
  • AHH Real Estate
  • Sector
  • CSTL Health Care
  • AHH Finance
  • Exchange
  • CSTL Nasdaq
  • AHH Nasdaq
  • Market Cap
  • CSTL 661.7M
  • AHH 600.4M
  • IPO Year
  • CSTL 2019
  • AHH 2013
  • Fundamental
  • Price
  • CSTL $22.14
  • AHH $6.58
  • Analyst Decision
  • CSTL Strong Buy
  • AHH Buy
  • Analyst Count
  • CSTL 6
  • AHH 4
  • Target Price
  • CSTL $37.67
  • AHH $8.38
  • AVG Volume (30 Days)
  • CSTL 296.4K
  • AHH 633.8K
  • Earning Date
  • CSTL 11-03-2025
  • AHH 11-03-2025
  • Dividend Yield
  • CSTL N/A
  • AHH 12.40%
  • EPS Growth
  • CSTL N/A
  • AHH N/A
  • EPS
  • CSTL N/A
  • AHH 0.13
  • Revenue
  • CSTL $346,269,000.00
  • AHH $544,168,000.00
  • Revenue This Year
  • CSTL N/A
  • AHH N/A
  • Revenue Next Year
  • CSTL N/A
  • AHH $2.61
  • P/E Ratio
  • CSTL N/A
  • AHH $51.06
  • Revenue Growth
  • CSTL 20.40
  • AHH N/A
  • 52 Week Low
  • CSTL $14.59
  • AHH $6.10
  • 52 Week High
  • CSTL $35.84
  • AHH $11.32
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 46.56
  • AHH 33.63
  • Support Level
  • CSTL $22.16
  • AHH $6.58
  • Resistance Level
  • CSTL $23.19
  • AHH $6.81
  • Average True Range (ATR)
  • CSTL 0.89
  • AHH 0.14
  • MACD
  • CSTL -0.16
  • AHH -0.02
  • Stochastic Oscillator
  • CSTL 10.05
  • AHH 3.43

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: